Julie E. Bauman, MD, MPH
Deputy Director
Clinical and Translational Oncology Program co-Leader
Professor and Chief, Division of Hematology/Oncology
Clinical and Translational Oncology Program
-
Deputy Director
Professor, Medicine
Division Chief, Hematology Oncology
Biography
Julie E. Bauman, MD, MPH is a Professor of Medicine, Chief of Hematology/Oncology and the Deputy Director at the University of Arizona Cancer Center. She received her MD/MPH degree from Tufts University, earning election to Alpha Omega Alpha and the MD/MPH Academic Achievement Award in 1999. She completed Internal Medicine Residency at University of Utah in 2003 and Medical Oncology Fellowship at University of Washington in 2006, where she was Chief Fellow. Her education and training, focused at intersection of oncology and public health, resulted in unique expertise in clinical trials for cancer prevention or treatment. Dr. Bauman is a Tucson local; she graduated from Salpointe HS in 1985.
Cancer Focus
Dr. Bauman is an internationally recognized expert in head and neck cancer (HNC). Her research program is dedicated to clinical trials to prevent or treat HNC, including multiple trials evaluating novel immunotherapies. She is the Co-Principal Investigator of the UArizona Cancer Center's Cancer Prevention Clinical Trials Network, which tests candidate prevention agents such as broccoli-based supplements to reduce tobacco carcinogenesis or HPV vaccination schedules to impart immunity. Dr. Bauman received the NCI Clinical Investigator Team Leadership Award in 2011. She is Co-Chair of the NCI Cancer Prevention Steering Committee and a Task Force member of the HNC Steering Committee. She sees patients with HNC and thyroid cancer at the UArizona Cancer Center clinic at Banner-University North.
Selected Publications
Bauman, J. E., J. Ohr, W. E. Gooding, R. L. Ferris, U. Duvvuri, S. Kim, J. T. Johnson, A. C. Soloff, G. Wallweber, J. Winslow, et al., "Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.", Cancers (Basel), vol. 12, issue 6, 2020 Jun 11. PMCID: PMC7352434 PMID: 32545260
Bauman, J. E., U. Duvvuri, S. Thomas, W. E. Gooding, D. A. Clump, B. Karlovits, A. Wehbe, F. R. Miller, S. Kim, M. Sen, et al., "Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.", Cancer, vol. 124, issue 19, pp. 3881-3889, 2018 Oct 01. PMCID: PMC6521720 PMID: 30291796
Bauman, J. E., U. Duvvuri, W. E. Gooding, T. J. Rath, N. D. Gross, J. Song, A. Jimeno, W. G. Yarbrough, F. M. Johnson, L. Wang, et al., "Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.", JCI Insight, vol. 2, issue 6, pp. e90449, 2017 Mar 23. PMCID: PMC5358497 PMID: 28352657
Bauman, J. E., E. Cohen, R. L. Ferris, D. J. Adelstein, D. M. Brizel, J. A. Ridge, B. O'Sullivan, B. A. Burtness, L. H. Butterfield, W. E. Carson, et al., "Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.", Cancer, vol. 123, issue 7, pp. 1259-1271, 2017 Apr 01. PMCID: PMC5705038 PMID: 27906454
Stabile, L. P., A. M. Egloff, M. K. Gibson, W. E. Gooding, J. Ohr, P. Zhou, N. J. Rothenberger, L. Wang, J. L. Geiger, J. T. Flaherty, et al., "IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.", Oral Oncol, vol. 69, pp. 38-45, 2017 06. PMCID: PMC5944328 PMID: 28559019
Bauman, J. E., Y. Zang, M. Sen, C. Li, L. Wang, P. A. Egner, J. W. Fahey, D. P. Normolle, J. R. Grandis, T. W. Kensler, et al., "Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.", Cancer Prev Res (Phila), vol. 9, issue 7, pp. 547-57, 2016 Jul. PMCID: PMC4930727 PMID: 27339168